Literature DB >> 17599719

Ethical issues in clinical neuroscience research: a patient's perspective.

Perry D Cohen1, Linda Herman, Sheryl Jedlinski, Peggy Willocks, Paula Wittekind.   

Abstract

A patient-centered paradigm for clinical research and medical care is presented as a solution to the problem of declining innovation and increasing costs and development time in the pipeline for new therapies. Fundamental differences in values and motivations among scientists, clinicians, industry sponsor, and patients in neurotherapeutics provide a framework for analysis of ethical conflicts and the loss of public confidence in medical research. Parkinson advocates' views on clinical trial participation, perceived risks and benefits, placebo controls, and sham surgery are presented. These views reflect the sense of urgency and the unique perspective that comes from living with this progressive, debilitating condition full time. A patient-centered paradigm that includes authentic voices of patients as collaborators at every stage of development will help to resolve conflicts, build trust, recruit trial participants, and accelerate new therapies. Key elements are adaptive clinical trial methods and the development of information technology for the assessment of outcomes and surveillance of safety over the life cycle of a medical product. Supported by the Parkinson's Disease Foundation, the Parkinson Pipeline Project is a grassroots group of Parkinson's patients whose goal is to represent an authentic voice for patients in the treatment development process. This group promotes education and communication between members of the Parkinson's community and active stakeholders in medical research, industry, and regulatory agencies. Its members are an example of a new breed of knowledgeable consumers, armed with first-hand access to research findings and reinforced by on-line connections to like-minded peers throughout the world.

Entities:  

Mesh:

Year:  2007        PMID: 17599719     DOI: 10.1016/j.nurt.2007.04.008

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  16 in total

1.  Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers.

Authors:  Scott Y H Kim; Samuel Frank; Robert Holloway; Carol Zimmerman; Renee Wilson; Karl Kieburtz
Journal:  Arch Neurol       Date:  2005-09

2.  The physician/investigator's obligation to patients participating in research: the case of placebo controlled trials.

Authors:  Kathleen Cranley Glass; Duff Waring
Journal:  J Law Med Ethics       Date:  2005       Impact factor: 1.718

3.  The hard way to a Bill of Rights.

Authors: 
Journal:  Lancet Neurol       Date:  2005-12       Impact factor: 44.182

Review 4.  Ethics, methodology and the use of placebo controls in surgical trials.

Authors:  Stephen Polgar; Joanna Ng
Journal:  Brain Res Bull       Date:  2005-10-30       Impact factor: 4.077

5.  GDNF in treatment of Parkinson's disease: response to editorial.

Authors:  Richard D Penn; Arif Dalvi; John Slevin; Byron Young; Don Gash; Greg Gerhardt; Michael Hutchinson
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

6.  Point source concentration of GDNF may explain failure of phase II clinical trial.

Authors:  Michael F Salvatore; Yi Ai; Brent Fischer; Amanda M Zhang; Richard C Grondin; Zhiming Zhang; Greg A Gerhardt; Don M Gash
Journal:  Exp Neurol       Date:  2006-09-07       Impact factor: 5.330

Review 7.  What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports.

Authors:  Samuel Frank; Karl Kieburtz; Robert Holloway; Scott Y H Kim
Journal:  Neurology       Date:  2005-07-20       Impact factor: 9.910

8.  Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial.

Authors:  Cynthia McRae; Eva Cherin; T Gayle Yamazaki; Gretchen Diem; Alexander H Vo; Dan Russell; J Heiner Ellgring; Stanley Fahn; Paul Greene; Sandra Dillon; Hal Winfield; Kimberly B Bjugstad; Curt R Freed
Journal:  Arch Gen Psychiatry       Date:  2004-04

Review 9.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

10.  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors:  Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

View more
  5 in total

1.  Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy.

Authors:  Holly L Peay; Aad Tibben; Tyler Fisher; Ethan Brenna; Barbara B Biesecker
Journal:  Clin Trials       Date:  2013-12-04       Impact factor: 2.486

2.  Increasing access to clinical research using an innovative mobile recruitment approach: The (MoRe) concept.

Authors:  Danielle Beck; Aliya Asghar; Tawni Kenworthy-Heinige; Marcus R Johnson; Cyenthia Willis; Alexandra S Kantorowicz; Debra L Condon; Grant D Huang
Journal:  Contemp Clin Trials Commun       Date:  2020-07-18

3.  Sham surgery trial controls: perspectives of patients and their relatives.

Authors:  Teresa L Swift
Journal:  J Empir Res Hum Res Ethics       Date:  2012-07       Impact factor: 1.742

4.  The 10-year Landscape of United States-Registered Parkinson Disease Clinical Trials: 2007-2016.

Authors:  Kara J Wyant; Erika Yasuda; Vikas Kotagal
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

Review 5.  Placebo in Surgical Research: A Case-Based Ethical Analysis and Practical Consequences.

Authors:  Sorin Hostiuc; Irina Rentea; Eduard Drima; Ionut Negoi
Journal:  Biomed Res Int       Date:  2016-08-10       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.